BPC-157, TB-500, and the wound-healing literature

BPC-157 — Body Protection Compound 157 — is a synthetic 15-amino-acid sequence (GEPPPGKPADDAGLV) isolated from a larger protective protein found in human gastric juice. The original Croatian research group, led by Sikirić, characterised the parent compound in the early 1990s and the 15-mer fragment in the late 1990s. It is sometimes referred to as PL-14736 or Pentadecapeptide BPC-157 in the literature.

TB-500 is the synthetic acetylated form of the active 17-amino-acid region of Thymosin Beta-4 (Tβ4) — a 43-amino-acid protein originally isolated from calf thymus by Goldstein and colleagues in the 1980s. Tβ4 is one of the most abundant cellular proteins in mammalian tissue; the TB-500 fragment was developed as a research analog that retains the actin-binding and angiogenic activity of the parent.

BPC-157's reported activity in research models centres on three pathways: nitric-oxide signalling (NO synthase modulation), VEGFR2 expression and downstream angiogenesis, and growth-factor receptor crosstalk (FGF, EGF, GH receptors). The peptide does not appear to bind a single high-affinity receptor — its effects are described as 'systemic' across organ systems in the published animal work.

TB-500 / Thymosin Beta-4 acts primarily as an actin-sequestering peptide. By binding G-actin and modulating the cytoskeleton, it has been implicated in cell migration, angiogenesis (via endothelial migration), and stem-cell mobilisation. Its half-life in plasma is short, but tissue persistence has been described as longer due to actin-bound depot effects.

Both peptides show overlapping outputs (angiogenesis, granulation tissue formation, reduced fibrosis in some models) but the upstream biology is distinct. Comparing the two in a single experimental design is non-trivial — the assays that detect BPC-157's nitric-oxide-dependent effects are different from those that detect TB-500's actin-binding kinetics.

BPC-157 has the densest published literature in gastrointestinal models (gastric ulcer, colitis, inflammatory bowel disease) and tendon/ligament repair. Most of this work is rodent or in-vitro; human research is limited to a small number of early-phase trials in inflammatory bowel disease, none of which has produced a marketed therapy.

TB-500 / Thymosin Beta-4 has been studied in cardiac repair (post-MI infarct models), corneal wound healing (the most clinically advanced application — RGN-259 reached late-stage human trials for dry eye and neurotrophic keratitis), neural injury models, and dermal wound healing. The corneal work is the closest the molecule has come to clinical use.

Both peptides are typically reconstituted in bacteriostatic water (0.9% benzyl alcohol) and stored at 2–8°C once in solution. Lyophilised vials are stable at room temperature for short windows but should be stored frozen for long-term work.

BPC-157 is comparatively stable and tolerant of standard handling. TB-500 is more sensitive to oxidation and freeze-thaw cycling — aliquoting after reconstitution is generally recommended for any multi-day study.

Common research molarities for in-vitro work: BPC-157 in the 1–10 μM range depending on cell line; TB-500 in the 1–100 nM range. As always with peptide work, dose-response runs first, single-dose comparisons second.